Clinical Trials Sponsored by Teva Pharmaceuticals Development, Inc.

Total 809 results

Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

Binge-Eating Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Agitation in Participants With Dementia of the Alzheimer's Type

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Intermittent Explosive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Atopic Dermatitis

Poland, United States, Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

Schizophrenia | Schizoaffective Disorder | First Episode Psychosis

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (ASPIRE)

Schizophrenia

United States, India, South Africa, Estonia, Russian Federation, Mexico, Korea, Republic of, Malaysia, Bulgaria, Hungary, Croatia, Serbia, Poland, Romania, Puerto Rico, Slovakia, Chile, Taiwan, Thailand, Australia, Spain, Argentina, Finlan... and more
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

Multidrug-resistant Tuberculosis

South Africa, Estonia, Philippines, Peru, Lithuania, Latvia, Moldova, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (Orion)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Russian Federation, Romania, Ukraine, Germany, Hungary, Slovakia, Serbia, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

Schizophrenia | Major Depressive Disorder | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

Hyponatremia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (EMPHASIS)

Chronic Obstructive Pulmonary Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Germany, United Kingdom, Spain, Sweden, Hungary, Czech Republic, Denmark
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Solid Tumors

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (ARRIVE- EU)

Schizophrenia

Belgium, Bulgaria, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tic Disorder | Tourette's Disorder

United States, Germany, Spain, Mexico, Romania, Canada, Hungary, Italy, Sweden
Otsuka Pharmaceutical Development & Commercialization...

Completed

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Schizophrenia | Mental Disorder | Bipolar 1 Disorder | Nervous System Disorders

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Bipolar I Disorder

United States, Argentina
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Alzheimer Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in Patients With a History of Bipolar Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

Alzheimer Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Oral Aripiprazole Open-Label Rollover Study

Schizophrenia

Russian Federation, Argentina, Croatia, India, Serbia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole Open-Label, Safety and Tolerability Study (APEX 241)

Schizophrenia | Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole in Adolescents With Schizophrenia (APEX 239)

Schizophrenia

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

Heart Failure, Congestive

United States, Romania
Otsuka Pharmaceutical Development & Commercialization...

Completed

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

Congestive Heart Failure

Canada, United States
COUR Pharmaceutical Development Company, Inc.

Recruiting

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Myasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MG

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Belgium, Canada, Chile, Colombia, Croatia, Hungary, Mexico, Netherlands, Slovakia, Slovenia, Spain, Ireland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Bulgaria, Denmark, Estonia, Greece, Poland, Portugal, Puerto Rico, United Kingdom, Germany, Ukraine

Clinical Trials Sponsored by Teva Pharmaceuticals Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations